Safety, tolerability, and efficacy trial of multiple daily administration of LFF571 for 10 days in patients with moderate Clostridium difficile infections

Registry ID

EUCTR2011-000947-26

Source registry

EUCTR

Status

Prematurely Ended

Phase

PHASE2

Sponsor

Novartis Farmacéutica S.A

Start date

2012-08-28

Last update

2026-08-16

Conditions

• Clostridium difficile infections

Summary

- To evaluate the clinical response (clinical cure) rates of patients with mild and moderate C. difficile infections to different LFF571 dose regimens and total daily doses adminisitered orally for 10 days. - To characterize the dose-response relationship of different dose regimens and total daily doses of LFF571. - To assess the safety and tolerability of different LFF571 dose regimens and total daily doses administered orally for 10 days to C. difficile infected patients.

Locations

• , , Portugal
• , , Spain

View on source registry